These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11425622)

  • 1. New light on polyglutamine neurodegenerative disorders: interference with transcription.
    Néri C
    Trends Mol Med; 2001 Jul; 7(7):283-4. PubMed ID: 11425622
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurodegeneration. A glutamine-rich trail leads to transcription factors.
    Freiman RN; Tjian R
    Science; 2002 Jun; 296(5576):2149-50. PubMed ID: 12077389
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
    Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
    Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyglutamine disease: acetyltransferases awry.
    Hughes RE
    Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
    Stenoien DL; Mielke M; Mancini MA
    Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
    Bates EA; Victor M; Jones AK; Shi Y; Hart AC
    J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.
    Cong SY; Pepers BA; Evert BO; Rubinsztein DC; Roos RA; van Ommen GJ; Dorsman JC
    Mol Cell Neurosci; 2005 Sep; 30(1):12-23. PubMed ID: 15994095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian Association of Neurosciences Review: polyglutamine expansion neurodegenerative diseases.
    Truant R; Raymond LA; Xia J; Pinchev D; Burtnik A; Atwal RS
    Can J Neurol Sci; 2006 Aug; 33(3):278-91. PubMed ID: 17001815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis.
    Chai Y; Shao J; Miller VM; Williams A; Paulson HL
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9310-5. PubMed ID: 12084819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamine repeats and neurodegenerative diseases: molecular aspects.
    Perutz MF
    Trends Biochem Sci; 1999 Feb; 24(2):58-63. PubMed ID: 10098399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein.
    Taylor JP; Taye AA; Campbell C; Kazemi-Esfarjani P; Fischbeck KH; Min KT
    Genes Dev; 2003 Jun; 17(12):1463-8. PubMed ID: 12815067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CREB-binding protein sequestration by expanded polyglutamine.
    McCampbell A; Taylor JP; Taye AA; Robitschek J; Li M; Walcott J; Merry D; Chai Y; Paulson H; Sobue G; Fischbeck KH
    Hum Mol Genet; 2000 Sep; 9(14):2197-202. PubMed ID: 10958659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
    Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
    Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1).
    Orr HT
    Neurobiol Dis; 2000 Jun; 7(3):129-34. PubMed ID: 10860780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyglutamine and CBP: fatal attraction?
    McCampbell A; Fischbeck KH
    Nat Med; 2001 May; 7(5):528-30. PubMed ID: 11329046
    [No Abstract]   [Full Text] [Related]  

  • 18. PGC-1alpha, a new therapeutic target in Huntington's disease?
    McGill JK; Beal MF
    Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspases and neurodegenerative diseases.
    Hafezparast M
    Mol Med Today; 2000 Sep; 6(9):338. PubMed ID: 11202967
    [No Abstract]   [Full Text] [Related]  

  • 20. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.